改良BFM-90方案治疗成人T淋巴母细胞淋巴瘤的疗效及安全性  

The efficacy and safety of modified BFM-90 regimen therapy on treatment of adult T lymphoblastic lymphoma

作　　者：王科峰[1] 夏忠军[1] 李苏[2] 陈晓勤[1] 李亚军[1] 王志辉[1] 吴肖志军[1] 

机构地区：[1]中山大学肿瘤防治中心,华南肿瘤学国家重点实验室血液肿瘤科,广州510060 [2]中山大学肿瘤防治中心,华南肿瘤学国家重点实验室GCP中心,广州510060

出　　处：《广东医学》2011年第24期3191-3194,共4页Guangdong Medical Journal

摘　　要：目的分析改良BFM-90方案治疗成人T淋巴母细胞淋巴瘤的疗效及安全性。方法经病理形态学确诊为T-淋巴母细胞淋巴瘤的36例成年患者,均接受我院改良的BFM-90方案治疗,观察该方案治疗的疗效和不良反应。结果 36例T淋巴母细胞淋巴瘤患者中26例患者存在明显纵隔肿块,22例患者出现骨髓侵犯。在诱导结束后,达完全缓解及不能确证完全缓解患者34例,部分缓解2例,总体有效率达100%。经中位随访29.5个月后,36例患者中,12例出现复发,其中8例死亡。在治疗过程中无治疗相关死亡。所有患者均出现Ⅲ/Ⅳ度骨髓抑制,经对症治疗可恢复。结论改良BFM-90方案为治疗成人T淋巴母细胞淋巴瘤安全且有效的方案,值得在临床继续使用。Objective To evaluate the efficacy and safety of modified BFM-90 protocol treatment on patients with T lymphoblastic lymphoma. Methods Thirty-six adult T lymphoblastic lymphoma patients,who were newly diagnozed according to the REAL classification,were enrolled in the study.The efficacy and toxicity of the modified BFM-90 regimen were analyzed. Results The median age of the 36 patients was 20(range from 15~55 years).Mediastinum mass and bone marrow involvement were revealed in 26 and 22 patients,respectively.At the end of induction,34 patients achieved CR or CRu and 2 achieved PR.The overall response rate was 100%.The median follow-up duration was 29.5 months.After that,12 cases of relapse and 8 deaths were observed.There was no death during the treatment.All patients presented III/IV degree myelosuppression,but all of them recovered after treatment. Conclusion The modified BFM-90 is an effective protocol for the treatment of adult T lymphoblastic lymphoma.

关 键 词：淋巴母细胞淋巴瘤 T细胞 联合化疗 不良反应 成人 

分 类 号：R733[医药卫生—肿瘤]